HUTCHMED Reports Phase III SANOVO PFS Benefit in EGFR NSCLC
Hong Kong, Shanghai & Florham Park, NJ – August 31, 2026 HUTCHMED (China) Limited announced positive high-level results from...
HUTCHMED
Advertisement
Roivant Wins FDA Approval for LISRAYA in Dermatomyositis
Basel, Switzerland, London, United Kingdom & New York – August 27, 2026 Roivant announced that the U.S. Food and...
HUTCHMED Wins NMPA Approval for ATLED in ICC
Hong Kong, Shanghai & Florham Park, New Jersey – August 28, 2026 HUTCHMED announced that China’s National Medical Products...
HUTCHMED and AstraZeneca Advance ORPATHYS-TAGRISSO Lung Cancer Combination
Hong Kong, Shanghai & Florham Park, N.J., Aug. 17, 2026 HUTCHMED (China) Limited announced positive high-level results from the...
HUTCHMED Wins NMPA Approval for ORPATHYS® in Gastric Cancer
Hong Kong, Shanghai & Florham Park, N.J., July 2, 2026 HUTCHMED has achieved a major regulatory milestone after the...
Advertisements
HUTCHMED Reports Strong Phase II Fanregratinib Data in ICC
HONG KONG, SHANGHAI & FLORHAM PARK, N.J., June 25, 2026 HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) announced that pivotal Phase II registration...
HUTCHMED Reports Positive Phase III Sovleplenib Results in wAIHA
Hong Kong, Shanghai & Florham Park, N.J., June 12, 2026 HUTCHMED (China) Limited announced positive results from the Phase...
HUTCHMED Advances Sovleplenib NDA for wAIHA in China
HONG KONG, SHANGHAI & FLORHAM PARK, N.J., April 29, 2026 HUTCHMED (China) Limited has announced that the New Drug...
HUTCHMED’s Savolitinib NDA Gains Priority Review in China
Hong Kong / Shanghai | December 30, 2025 — HUTCHMED announced that China’s drug regulator has accepted the New...
Advertisement
